Chemotherapy-free neoadjuvant regimen with durvalumab, trastuzumab and pertuzumab (DTP) in HER2-enriched early breast cancer: A prospective, open-label phase II trial

Sunil  Mathur

Chemotherapy-free neoadjuvant regimen with durvalumab, trastuzumab and pertuzumab (DTP) in HER2-enriched early breast cancer: A prospective, open-label phase II trial

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution

Abstract

Guan, J., Sun, K., Jain, D., Mathur, S., Mai, H., Niravath, P., & Chang, J. (2024, April). Chemotherapy-free neoadjuvant regimen with durvalumab, trastuzumab and pertuzumab (DTP) in HER2-enriched early breast cancer: A prospective, open-label phase II trial. In CANCER RESEARCH (Vol. 84, No. 7). AMER ASSOC CANCER RESEARCH.

Original language	English (US)
Title of host publication	CANCER RESEARCH. Vol. 84. No. 7. 615
State	Published - 2024

Cite this

@inproceedings{cc65ee7585cd4c0799d8d15d915c41fc,

title = "Chemotherapy-free neoadjuvant regimen with durvalumab, trastuzumab and pertuzumab (DTP) in HER2-enriched early breast cancer: A prospective, open-label phase II trial",

abstract = "Guan, J., Sun, K., Jain, D., Mathur, S., Mai, H., Niravath, P., \& Chang, J. (2024, April). Chemotherapy-free neoadjuvant regimen with durvalumab, trastuzumab and pertuzumab (DTP) in HER2-enriched early breast cancer: A prospective, open-label phase II trial. In CANCER RESEARCH (Vol. 84, No. 7). AMER ASSOC CANCER RESEARCH.",

author = "Sunil Mathur",

year = "2024",

language = "English (US)",

booktitle = "CANCER RESEARCH. Vol. 84. No. 7. 615",

}

TY - GEN

T1 - Chemotherapy-free neoadjuvant regimen with durvalumab, trastuzumab and pertuzumab (DTP) in HER2-enriched early breast cancer: A prospective, open-label phase II trial

AU - Mathur, Sunil

PY - 2024

Y1 - 2024

N2 - Guan, J., Sun, K., Jain, D., Mathur, S., Mai, H., Niravath, P., & Chang, J. (2024, April). Chemotherapy-free neoadjuvant regimen with durvalumab, trastuzumab and pertuzumab (DTP) in HER2-enriched early breast cancer: A prospective, open-label phase II trial. In CANCER RESEARCH (Vol. 84, No. 7). AMER ASSOC CANCER RESEARCH.

AB - Guan, J., Sun, K., Jain, D., Mathur, S., Mai, H., Niravath, P., & Chang, J. (2024, April). Chemotherapy-free neoadjuvant regimen with durvalumab, trastuzumab and pertuzumab (DTP) in HER2-enriched early breast cancer: A prospective, open-label phase II trial. In CANCER RESEARCH (Vol. 84, No. 7). AMER ASSOC CANCER RESEARCH.

M3 - Conference contribution

BT - CANCER RESEARCH. Vol. 84. No. 7. 615

ER -

Chemotherapy-free neoadjuvant regimen with durvalumab, trastuzumab and pertuzumab (DTP) in HER2-enriched early breast cancer: A prospective, open-label phase II trial

Abstract

Fingerprint

Cite this